LOFMARK PTY LTD – Trademark Portfolio

Entity Type: 03

LOFMARK PTY LTD holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 32 (Light Beverages) across 2 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include COMEBACK and COMEBACK COMPLEMENTS. The owner is based in Earlwood NSW.

1/157 Homer Street

Earlwood NSW 2206 , AU

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

LOFMARK PTY LTD's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (8 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

32
Light Beverages (7 filings)

Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages

Frequently Asked Questions

How many trademarks does LOFMARK PTY LTD have?

LOFMARK PTY LTD has 8 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 3 abandoned, 2 cancelled.

What trademark classes does LOFMARK PTY LTD file in?

LOFMARK PTY LTD files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 32 (Light Beverages). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are LOFMARK PTY LTD's most well-known trademarks?

LOFMARK PTY LTD's registered trademark portfolio includes well-known marks such as COMEBACK and COMEBACK COMPLEMENTS. These are among 2 currently registered trademarks in the portfolio.

What is LOFMARK PTY LTD's trademark registration success rate?

LOFMARK PTY LTD has a 29% trademark registration rate, with 2 out of 7 resolved applications resulting in successful registration. Currently, 1 application is pending review.